Restoration Hardware Holdings Inc

Most Recent

  • uploads///quarterly revenue
    Company & Industry Overviews

    Understanding Pfizer’s 3Q16 Performance

    During 3Q16, Pfizer (PFE) recorded revenue amounting to $13 billion. Excluding the impact of foreign exchange, the company’s revenue rose 8% annually.

    By Jillian Dabney
  • uploads///teva loss
    Company & Industry Overviews

    Teva Pharmaceutical: Earnings Trends and Recent Developments

    Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

    By Daniel Collins
  • uploads///Avastin
    Company & Industry Overviews

    A Performance Update for Roche’s Avastin in H2 2018

    In June, the FDA approved Avastin in combination with chemotherapy followed by Avastin monotherapy.

    By Daniel Collins
  • uploads///Featured image
    Company & Industry Overviews

    A Look into Roche Holding’s Performance in Q1 2018

    In Q1 2018, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in Q1 2017.

    By Daniel Collins
  • uploads///Eylea
    Earnings Report

    Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?

    Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US.

    By Jillian Dabney
  • uploads///ANR
    Earnings Report

    What Do Analysts Recommend for Medivation?

    According to a Bloomberg consensus of 21 brokerage firms dated May 9, 57.9% rated Medivation a “buy” and 42.1% rated it a “hold.”

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    What Could Expand Keytruda’s Revenues?

    In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.

    By Margaret Patrick
  • uploads///Hemlibra
    Company & Industry Overviews

    Roche’s Hemlibra Could Drive Long-Term Growth

    In the first quarter, Roche’s (RHHBY) Hemlibra generated revenues of 23 million Swiss francs.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    How Biogen’s Tysabri and Zinbryta Performed in 1Q17

    In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets.

    By Margaret Patrick
  • uploads///PE
    Company & Industry Overviews

    Understanding the Recent Fall in Bristol-Myers Squibb’s Valuation

    On October 4, 2016, Bristol-Myers Squibb (BMY) was trading at a forward PE (price-to-earnings) multiple of 16.8x. With products Opdivo and Yervoy, the company leads the immuno-oncology space.

    By Jillian Dabney
  • uploads///Xalkori Inlyta
    Company & Industry Overviews

    How Are Pfizer’s Xalkori and Inlyta Positioned in 2017?

    In 2016, Pfizer’s (PFE) Xalkori reported revenues of ~$561 million, which reflected a ~15% YoY (year-over-year) rise.

    By Daniel Collins
  • uploads///roche tecentriq
    Company & Industry Overviews

    Recent Developments with Roche’s Lung Cancer Drug Tecentriq

    On April 9, 2018, Roche (RHHBY) said it has received approval for Tecentriq from NICE for the treatment of the most common form of lung cancer.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Venclexta May Prove a Novel Chemotherapy-Free Treatment Option

    In 2017, AbbVie (ABBV) and Roche Holdings’ (RHHBY) Venclexta reported positive data from its Phase 3 trial, MURANO.

    By Margaret Patrick
  • uploads///Orkambi
    Earnings Report

    How Vertex Pharmaceuticals’ Drugs Performed in 1Q18

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Why Eylea Could Face Tough Competition in 2016

    In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

    By Mike Benson
  • uploads///Oncology
    Company & Industry Overviews

    A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta

    In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Amgen’s Nephrology Drugs Expect Falling Revenue in 4Q15

    Analysts projected a fall in the revenue for Amgen’s nephrology drugs, Aranesp and Epogen, in 4Q15. The drugs are expected to suffer in the coming quarters.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s New Oncology Portfolio May See Healthy Growth

    In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Product Line Extension

    As part of its significant product line extension, Gilead Sciences (GILD) is entering therapeutic areas such as oncology, pulmonology, and cardiology.

    By Margaret Patrick
  • uploads///Eylea sales
    Earnings Report

    Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?

    Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.

    By Jillian Dabney
  • uploads///ocrevus
    Company & Industry Overviews

    Why NICE Didn’t Approve Roche’s Ocrevus for Multiple Sclerosis

    On April 5, 2018, Roche’s (RHHBY) MS (multiple sclerosis) drug Ocrevus was denied recommendation by NICE.

    By Sarah Collins
  • uploads///effects of salix disposal
    Company & Industry Overviews

    How Could a Salix Sale Impact Valeant’s Financials?

    With the sale of Salix, Valeant’s adjusted revenues will fall 14.0%. Since Salix is a high-margin business, the sale will adversely impact Valeant’s margins.

    By Jillian Dabney
  • uploads///ibrance
    Company & Industry Overviews

    Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer

    Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.

    By Jillian Dabney
  • uploads///lung cancer
    Company & Industry Overviews

    Why Is Lung Cancer so Attractive to Bristol, Merck, and Roche?

    Bristol-Myers Squibb’s (BMY) Opdivo’s will now share the second-line lung cancer therapy market with Roche’s Tecentriq, along with Merck’s Keytruda.

    By Jillian Dabney
  • uploads///Eylea
    Company & Industry Overviews

    How Regeneron Is Working to Maintain Eylea’s Dominance

    Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.

    By Jillian Dabney
  • uploads///Celator pipeline
    Company & Industry Overviews

    How Can Celator’s Portfolio Complement Jazz Pharmaceuticals?

    Vyxeos would offer commercial synergies to the Jazz Pharmaceuticals portfolio in the form of a complementary targeted prescriber base of AML patients who undergo HSCT.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca Is Taking Steps to Improve Its Position in Oncology

    During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

    By Mike Benson
  • uploads///cancer _
    Company & Industry Overviews

    Tesaro Stock Up over 16% on Rumors of Acquisition by Roche

    Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.

    By Sarah Collins
  • uploads///RD
    Company & Industry Overviews

    What Were Pfizer’s Major Achievements in 2016?

    During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.

    By Jillian Dabney
  • uploads///pharma division performance
    Earnings Report

    Sales Performance Analysis of Roche’s Pharmaceuticals Division

    Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017

    On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    The High Hope of Exelixis’s Cabometyx Label Expansion

    Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

    By Margaret Patrick
  • uploads///breast Vs prostate cancer
    Company & Industry Overviews

    Could Xtandi’s Use for Breast Cancer Be a Valuation Driver?

    If Xtandi is successful in achieving a longer treatment duration of about ten months, it could earn up to $1 billion in the breast cancer space.

    By Jillian Dabney
  • uploads///Ibrance
    Company & Industry Overviews

    Analyzing Pfizer’s Ibrance and Xalkori after 2Q17

    In the US market in 4Q17, Ibrance generated revenues of $777 million, which reflected ~27% growth on a YoY basis.

    By Daniel Collins
  • uploads///PD L avelumab
    Company & Industry Overviews

    Exploring Avelumab’s Opportunities in the PD-1/PD-L1 Space

    Pfizer plans to use avelumab, a PD-L1 (programmed death-ligand 1) class immuno-oncology product, as a backbone therapy in its immuno-oncology programs.

    By Jillian Dabney
  • uploads///hemlibra
    Company & Industry Overviews

    Roche on Damage Control after Hemlibra Patient Deaths

    The news that five patients on Roche’s (RHHBY) hemophilia drug Hemlibra died triggered the stock to decline 2% on March 28, 2018.

    By Sarah Collins
  • uploads///Eylea
    Earnings Report

    What Drove Regeneron’s 3Q16 Performance?

    In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.

    By Jillian Dabney
  • uploads///
    Earnings Report

    Parsing Alphabet’s Other Bets Business

    Alphabet’s (GOOGL) Other Bets continued to grow in 4Q17 and actually accelerated from the previous quarter.

    By Neha Gupta
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Key Focus: Oncology

    AstraZeneca’s (AZN) key focus is its oncology segment. The segment’s contribution increased to more than 12% in 1Q16. Its key products include Zoladex, Faslodex, and Iressa.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017

    Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    This Could Be a Solid Growth Driver for Myriad Genetics in 2018

    Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Oncology Segment: Another Growth Platform for AstraZeneca?

    The oncology segment is another key focus area of AstraZeneca (AZN). The oncology segment’s contribution increased from ~11.6% in 2014 to ~12.1% in 2015.

    By Mike Benson
  • uploads///Performance of Some International Mutual Funds
    Company & Industry Overviews

    International Mutual Funds: Could They Be Suitable for You?

    For those investors who want to invest in international mutual funds, we’ve quantitatively analyzed the composition and performance of nine of them.

    By David Ashworth
  • uploads///Eylea
    Company & Industry Overviews

    Eylea Could Continue to Generate High Revenue

    Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.

    By Daniel Collins
  • uploads///Oncology Franchise
    Company & Industry Overviews

    The Latest on TEVA’s Oncology Business

    In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Xtandi’s Prescription Volumes Continue to Rise in 2017

    In this series, we’ll look at Pfizer’s main revenue drivers in 2017, and what could steer its performance in 2018.

    By Margaret Patrick
  • uploads///ROCHE  PHARMA
    Company & Industry Overviews

    Roche Gets Lung Cancer Drug Alecensa Approval in Swiss Market

    On April 3, 2018, Roche (RHHBY) announced that Alecensa was approved in Switzerland as a first-line treatment for ALK-positive NSCLC.

    By Sarah Collins
  • uploads///long term strtegy
    Earnings Report

    Inside Roche’s Strategy to Offset Revenue Declines

    Roche’s big three contributors include MabThera/Rituxan, Herceptin, and Avastin, which accounted for 14.7%, 13.9% and 13.7% of revenues in fiscal 1Q16.

    By Jillian Dabney
  • uploads///dementia _
    Company & Industry Overviews

    Biogen Stock Up on Alzheimer Trial Success

    Biogen (BIIB) stock recorded premarket gains of ~20% today, triggered by news of the success of a phase 2 study for BAN2401 for Alzheimer’s in collaboration with Eisai Corporation yesterday.

    By Sarah Collins
  • uploads///Roche growth
    Company & Industry Overviews

    Why Roche Might Be Interested in BioMarin

    With increased M&A activity in the pharmaceuticals and biotechnology space, it wouldn’t be surprising if Roche Holding (RHHBY) acquired BioMarin (BMRN).

    By Jillian Dabney
  • uploads///Abraxane
    Company & Industry Overviews

    How’s Celgene’s Abraxane Positioned after 4Q17?

    In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Keytruda
    Company & Industry Overviews

    Merck’s Keytruda Witnessed Solid Growth in First Half of 2018

    In Q2 2018, Merck’s (MRK) Keytruda generated revenues of $1.67 billion compared to $881.0 million in Q2 2017, reflecting ~89% YoY growth.

    By Daniel Collins
  • uploads///Imbruvica
    Company & Industry Overviews

    AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

    AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Chart  Ph
    Company & Industry Overviews

    Why GlaxoSmithKline’s Pharmaceuticals Business Grew

    GlaxoSmithKline is a major shareholder of ViiV Healthcare. Its HIV products reported revenue of 1.12 billion pounds during 2Q17.

    By Mike Benson
  • uploads///revenue proj
    Earnings Report

    Gauging Growth Expectations for Roche in 2Q16 and 2016

    Analysts project that Roche will earn revenues of 12.5 billion in swiss francs during the second quarter of 2016—a YoY growth of 6.3% during the period.

    By Jillian Dabney
  • uploads///PD  class action
    Company & Industry Overviews

    Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

    The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    What Drove Gilead Sciences’ Hepatitis C Portfolio in 3Q15?

    Gilead Sciences’ (GILD) hepatitis C (or HCV) portfolio is expected to continue driving the company’s revenues and net profit margins in 3Q15.

    By Margaret Patrick
  • uploads///ANR
    Earnings Report

    What Can Investors Expect from Regeneron’s 4Q15 Earnings?

    Regeneron will report its earnings for 4Q15 and fiscal 2015 on February 9, 2016. It will report the earnings before the financial markets open in the US.

    By Jillian Dabney
  • uploads///Ignyta Pipeline
    Company & Industry Overviews

    Ignyta’s Drug Pipeline

    Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    AbbVie’s Venclexta for Chronic Lymphocytic Leukemia

    AbbVie (ABBV) and Roche Holdings (RHHBY) have strategized to position Venclexta as a foundation therapy in the chronic lymphocytic leukemia (or CLL) indication.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Generics and Biosimilar Business Is Major Growth Driver for Teva

    Teva Pharmaceutical aims to launch the generic version of EpiPen in the US in the fourth quarter.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Mylan’s Key Growth Drivers in Fiscal 2019?

    In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    How Sanofi’s Rare Blood Disorder Portfolio Performed in Q1

    In the first quarter, Sanofi’s Rare Blood Disorder franchise reported net sales of 274 million euros.

    By Margaret Patrick
  • uploads///
    Company & Industry Overviews

    How Snap Wants to Beat Facebook in the Drug Advertising Market

    Snap (SNAP) is pursuing pharmaceutical companies to advertise on Snapchat, its social network used by some 186 million people worldwide.

    By Neha Gupta
  • uploads///Graph
    Company & Industry Overviews

    Most Analysts Have Given bluebird bio Positive Ratings in March

    Wall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing price on March 27.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Spark’s Potential Revenue Contribution to Roche Holdings

    Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

    By Margaret Patrick
  • uploads///merger _
    Healthcare

    Roche Holdings to Acquire Spark Therapeutics

    On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

    By Margaret Patrick
  • uploads///stock market pic
    Company & Industry Overviews

    Why AC Immune SA Stock Crashed on January 30

    On January 30, AC Immune SA (ACIU) issued a press release announcing the discontinuation of Phase 3 trials CREAD 1 and CREAD 2.

    By Margaret Patrick
  • uploads///Sutent
    Company & Industry Overviews

    How Pfizer’s Sutent and Xalkori Have Performed

    In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.

    By Daniel Collins
  • uploads///Europe
    Company & Industry Overviews

    Teva Pharmaceutical’s Performance in European Markets

    In the third quarter, Teva Pharmaceutical’s (TEVA) European revenue fell ~12% YoY (year-over-year) to $1.2 billion from $1.38 billion.

    By Daniel Collins
  • uploads///Roche
    Company & Industry Overviews

    An Update on Roche’s Neurology Business

    In October, Roche announced new interim data from the dose-evaluation sections of the FIREFISH and SUNFISH trials.

    By Daniel Collins
  • uploads///IONS
    Company & Industry Overviews

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.

    By Daniel Collins
  • uploads///glowing _
    Company & Industry Overviews

    Verastem Stock Plunged 19.98% Yesterday

    On September 25, Verastem (VSTM) stock fell to $7.15, a ~19.98% fall from its previous close of $8.93.

    By Daniel Collins
  • uploads///Graph
    Miscellaneous

    TransCon Tech Is a Major Growth Driver for Ascendis Pharma A/S

    Ascendis Pharma A/S (ASND) is a biopharmaceutical company focused on becoming a leading player in the endocrinology rare disease space.

    By Margaret Patrick
  • uploads///Keytruda
    Company & Industry Overviews

    How Is Merck’s Keytruda Positioned in September?

    Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion.

    By Daniel Collins
  • uploads///Activase
    Company & Industry Overviews

    How Roche’s Activase, Mircera, and Epogin Look in August

    In the second quarter, NeoRecormon/Epogin generated revenues of 79.0 million Swiss francs, reflecting an ~4% YoY decline at CER.

    By Daniel Collins
  • uploads///Ocrevus
    Company & Industry Overviews

    Ocrevus Could Boost Roche’s Revenue Growth in 2018 and Beyond

    In the second quarter, Ocrevus reported revenues of 561.0 million Swiss francs, which reflected ~195% YoY growth at CER.

    By Daniel Collins
  • uploads///Tamiflu
    Company & Industry Overviews

    How Is Roche’s Infectious Disease Business Positioned in August?

    In the second quarter, Rocephin generated revenues of 63.0 million Swiss francs, reflecting an ~14% YoY decline at CER.

    By Daniel Collins
  • Company & Industry Overviews

    An Overview of Roche’s Immunology Drugs Pulmozyme and CellCept

    Roche’s CellCept generated revenues of 333.0 million Swiss francs in H1 2018 compared to 346.0 million Swiss francs in H1 2017.

    By Daniel Collins
  • uploads///Actemra
    Company & Industry Overviews

    Roche’s Immunology Drug Actemra: A Long-Term Growth Driver?

    Roche’s (RHHBY) Actemra/RoActemra reported revenues of 1.05 billion Swiss francs in H1 2018 compared to 922.0 million Swiss francs in H1 2017.

    By Daniel Collins
  • uploads///Rituxan
    Company & Industry Overviews

    An Overview of Roche’s Hemato-Oncology Drugs MabThera and Gazvya

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 3.45 billion Swiss francs in the first half compared to 3.8 billion Swiss francs in the first half of 2017.

    By Daniel Collins
  • uploads///Diagnostics segment
    Healthcare

    How Is Roche’s Diagnostics Segments Positioned in August?

    Roche’s tissue diagnostics unit generated revenues of 290.0 million Swiss francs in the second quarter, reflecting ~15% YoY growth at CER.

    By Daniel Collins
  • uploads///capsule _
    Company & Industry Overviews

    An Update on Roche’s Immunology Drugs: Xolair and Esbriet

    Roche’s (RHHBY) Xolair reported revenues of 928.0 million Swiss francs in H1 2018, compared to 866.0 million Swiss francs in H1 2017.

    By Daniel Collins
  • uploads///Tecentriq
    Company & Industry Overviews

    Tecentriq Could Boost Roche’s Revenue Growth in 2018 and Beyond

    Roche’s (RHHBY) Tecentriq generated revenues of 320.0 million Swiss francs in the first half compared to 237.0 million Swiss francs in the first half of 2017.

    By Daniel Collins
  • uploads///Diagnostics
    Company & Industry Overviews

    A Performance Overview of Roche’s Diagnostics Division

    In July, Roche received the CE Mark for its Accu-Chek Solo micropump system.

    By Daniel Collins
  • uploads///RPH
    Company & Industry Overviews

    A Performance Update on Roche’s Pharmaceuticals Segment in August

    Roche’s (RHHBY) Pharmaceuticals division reported revenues of 21.8 billion Swiss francs in H1 2018 compared to 20.5 billion Swiss francs in H1 2017, reflecting ~7% YoY growth.

    By Daniel Collins
  • uploads///Alecensa
    Company & Industry Overviews

    Alecensa Could Boost Roche’s Revenue Growth in 2018 and Beyond

    Roche’s (RHHBY) Alecensa generated revenues of 279.0 million Swiss francs in the first half compared to 148.0 million Swiss francs in the first half of 2017.

    By Daniel Collins
  • uploads///Revenues
    Company & Industry Overviews

    Roche’s Financial Overview in August

    In H1 2018, Roche reported its cost of sales of 8.0 billion Swiss francs compared to 8.8 billion Swiss francs in H1 2017, which reflected an ~8.0% YoY decline.

    By Daniel Collins
  • uploads///close up _
    Company & Industry Overviews

    Update on Roche’s Oncology Drugs: Tarceva, Cotellic, and Erivedge

    Roche’s (RHHBY) Tarceva generated revenues of 298.0 million Swiss francs in H1 2018 compared to 436.0 million Swiss francs in H1 2017.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Tecfidera and Tysabri Still Driving Biogen’s Revenue Growth

    Biogen expects to witness robust demand trends for Tecfidera in ex-US markets in 2018.

    By Margaret Patrick
  • uploads///world _
    Company & Industry Overviews

    AbbVie’s Supplemental New Drug Application for Venetoclax

    On July 12, AbbVie (ABBV) announced that it had submitted an sNDA (supplemental new drug application) to the FDA for venetoclax.

    By Kenneth Smith
  • uploads///sym
    Company & Industry Overviews

    Could Symdeko Be Vertex Pharmaceuticals’ Long-Term Growth Driver?

    In June, Health Canada approved Vertex Pharmaceuticals’ Symdeko for the treatment of the underlying cause of cystic fibrosis in individuals over 12 years old.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

    On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Yesterday, PTC Therapeutics (PTCT) registered a stock price rise of ~24.6% on the positive data the company presented along with partner Roche (RHHBY) for their SMA (spinal muscular atrophy) drug risdiplam.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Envision Healthcare to Be Acquired by KKR

    On June 11, Envision entered into a definitive acquisition agreement with KKR.

    By Mike Benson
  • uploads///Label expansion Keytruda
    Company & Industry Overviews

    Keytruda’s Label Expansion Could Boost Merck’s Revenue Growth

    In June, the FDA approved Merck’s Keytruda for the treatment of metastatic cervical cancer patients whose disease had progressed after or during chemotherapy and whose tumors expressed PD-L1.

    By Daniel Collins
  • uploads///Keytruda revenues
    Company & Industry Overviews

    Merck’s Keytruda Receives a New Approval

    In June, the FDA approved Merck & Company’s Keytruda for the treatment of individuals with refractory primary mediastinal large B-cell lymphoma.

    By Daniel Collins
  • uploads///Featured image
    Company & Industry Overviews

    Teva Stock Could Jump after Good News from Partner Manufacturers

    Eagle Pharmaceuticals, one of Teva’s partners, won a lawsuit against the FDA for not granting orphan drug status to Bendeka.

    By Daniel Collins
  • uploads///scientist drugstore microscope
    Company & Industry Overviews

    Nektar Therapeutics’ Share Price Fell 41.8% on June 4

    On June 4, Nektar Therapeutics (NKTR) closed at $52.6—almost 41.8% lower than its previous close of $90.35.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.